Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 7Carcinoma, Transitional Cell 7Ureteral Neoplasms 3Urologic Neoplasms 2Neoplasm Metastasis 2Urothelial Cancer 1Urologic Diseases 1Urogenital Neoplasms 1Urogenital Diseases 1Urinary Bladder Diseases 1Urethral Neoplasms 1Peripheral Nervous System Diseases 1Neoplasms by Site 1Neoplasms 1Muscle-invasive Bladder Cancer 1Muscle Invasive Bladder Urothelial Carcinoma 1Male Urogenital Diseases 1Female Urogenital Diseases 1Adenocarcinoma of the Bladder 1

Interventions

Specimen Handling 40Biopsy 32Magnetic Resonance Spectroscopy 26pembrolizumab 20Nivolumab 10trastuzumab deruxtecan 9Paclitaxel 9Carboplatin 9Radiosurgery 7Irinotecan 7Gemcitabine 7X-Rays 6Pemetrexed 6Leucovorin 6Ipilimumab 6Fulvestrant 6Fluorouracil 6Cetuximab 6Bevacizumab 6palbociclib 5Taxes 5Oxaliplatin 5Cisplatin 5Capecitabine 5130-nm albumin-bound paclitaxel 5durvalumab 4Letrozole 4CTLA-4 Antigen 4ribociclib 3olaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × enfortumab vedotin × 30 days × Clear all
NCT06311214 2026-05-27

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
500 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05614739 2026-05-19

FORAGER-1

Eli Lilly and Company

Phase 1 Recruiting
535 enrolled
Genitourinary

Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡